Swipe for more

• October 19, 2023

  bioMérieux makes strategic investment in Oxford Nanopore

  Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics (“IVD”) today announce that bioMérieux is making an immediate £70M investment in Oxford Nanopore.

  Read more
  

• October 13, 2023

  bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1)

  bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE-marking of VIDAS® TBI (GFAP, UCH-L1), a blood test to support assessment of patients with mild traumatic brain injury (mTBI), based on a unique combination of brain biomarkers: GFAP and UCH-L1*.

  Read more
  

• October 11, 2023

  Launch of a new industrial chair, in Lyon on viral respiratory infections

  On October 11, 2023, the REVIDA Industrial Chair for Respiratory Infectious Diseases, led by researcher Sophie Trouillet-Assant (UCBL / HCL), was officially launched by Claude Bernard Lyon 1 University, Hospices Civils de Lyon, and bioMérieux, with the support of the Agence nationale de la recherche (National research agency, in France).

  Read more